Literature DB >> 212280

Chronic naloxone results in prolonged increases in opiate binding sites in brain.

R A Lahti, R J Collins.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 212280     DOI: 10.1016/0014-2999(78)90343-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


× No keyword cloud information.
  12 in total

1.  Involvement of mu-opioid receptors in the antitussive effects of pentazocine.

Authors:  J Kamei; K Katsuma; Y Kasuya
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-02       Impact factor: 3.000

2.  Increased sensitivity to rate-altering and discriminative stimulus effects of morphine following continuous exposure to naltrexone.

Authors:  A M Young; S R Mattox; M D Doty
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  Inability of an opioid antagonist lacking negative intrinsic activity to induce opioid receptor up-regulation in vivo.

Authors:  B J Morris; M J Millan
Journal:  Br J Pharmacol       Date:  1991-04       Impact factor: 8.739

4.  Conditioning of morphine-induced taste aversion and analgesia.

Authors:  J S Miller; K S Kelly; J L Neisewander; D F McCoy; M T Bardo
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

5.  Chronic naloxone increases opiate binding in SHR and WKY rats.

Authors:  E F Hahn
Journal:  Neurochem Res       Date:  1984-12       Impact factor: 3.996

6.  Pharmacological specificity of enhanced sensitivity to naltrexone in rats.

Authors:  C W Schindler; S R Goldberg; J L Katz
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Blockade of tolerance to morphine but not to kappa opioids by a nitric oxide synthase inhibitor.

Authors:  Y A Kolesnikov; C G Pick; G Ciszewska; G W Pasternak
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

8.  The effect of chronic treatment with naltrindole, a selective delta-opioid antagonist, on mu-opioid receptor-mediated antinociception in diabetic mice.

Authors:  J Kamei; N Kawashima; Y Iwamoto; T Suzuki; H Nagase; M Misawa; Y Kasuya
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 9.  New directions in migraine.

Authors:  Greg A Weir; M Zameel Cader
Journal:  BMC Med       Date:  2011-10-25       Impact factor: 8.775

Review 10.  Chaperone-like effects of cell-permeant ligands on opioid receptors.

Authors:  Yong Chen; Lee-Yuan Liu-Chen
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.